Gamma-aminobutyric acid type A receptor Benzodiazepine Binding Site

The Gamma-aminobutyric acid type A receptor (GABAA receptor) Benzodiazepine Binding Site is a specific binding site located at the interface between alpha (α) and gamma (γ) subunits of the GABAA receptor. This binding site is distinct from the GABA binding site, which is located at the interface between alpha (α) and beta (β) subunits. It is positioned at the α/γ subunit interface in a homologous position to the agonist (GABA) site, found in the N-terminal extracellular domain (ECD). The binding site consists of multiple subsites that can be occupied by ligands either independently or simultaneously, depending on the size and structure of the ligand. Studies using proximity-accelerated chemical reaction techniques have revealed that the C1 atom of diazepam is located close to α1His-101 and the 3'-atom of diazepam is positioned near α1Ser-205 and α1Thr-206. Research has identified different binding modes for various benzodiazepines, including CBM I binding mode used by ester-substituted imidazobenzodiazepines and CBM II binding mode employed by compounds derived from diazepam or triazolam. These distinct binding modes explain why different benzodiazepines can have varying pharmacological effects despite binding to the same general site. When benzodiazepines bind to this site, they induce allosteric modulation of the GABAA receptor structure. This conformational change enhances the action of GABA at the receptor, resulting in increased chloride ion conductance through the central channel. The binding of benzodiazepines does not directly activate the receptor but potentiates the effect of GABA binding. The benzodiazepine binding site is clinically significant as it is the target for benzodiazepine drugs, which are used for their anxiolytic effects, anticonvulsant properties, muscle relaxant capabilities, and sedative-hypnotic actions. Different benzodiazepines can have distinct binding modes at this site, which contributes to their varied pharmacological profiles and clinical effects. The benzodiazepine binding site represents an important target for drug discovery, with ongoing research focused on developing more selective compounds with improved therapeutic profiles and reduced side effects.

Allosteric modulation of GABAA receptor function, enhancement of GABA-induced chloride ion conductance, potentiation of inhibitory neurotransmission.